Share 'Webinar: ACT DMD Update with PTC'
On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD).
You can share this event in two ways…
© 2020 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
